Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population

Semmelweis University

Status and phase: Completed; Phase 4

Conditions: Chronic Central Serous Chorioretinopathy

Treatments: Drug: Inspra (eplerenone)

Study type: Interventional

Funder types: Other

Identifiers

NCT02462499

CSCR 104/2014

Details and patient eligibility

About

The aim of the study is to determine the efficacy and safety of treatment with the drug eplerenone in patients with chronic central serous chorioretinopathy.

Enrollment: 28 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Chronic central serous chorioretinopathy (CSCR) with persistent subretinal fluid on OCT for more than 3 months after initial presentation .
• Written informed consent

Exclusion criteria

• Persons with impaired decision-making ability.
• Pregnant women or who are actively trying to conceive.
• Additional eye disease affecting the macula or posterior retina.
• Creatinine clearance < 50 ml/min
• Hyperkalemia > 5 mmol/l
• Serum creatinine > 2 mg/dl in men or > 1.8 mg/dl in women
• Treatment with potassium sparing agents or potassium
• Treatment with any other drugs known to cause interaction with eplerenone
• Microalbuminuria in patients with type 2 diabetes

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

28 participants in 1 patient group

Treatment

Experimental group

Description:

Treatment: Eplerenone (Inspra) All patients will receive 25mg eplerenone once a day for a week, followed by 50mg once a day, for a total of 4-12 weeks.

Treatment:

Drug: Inspra (eplerenone)